(Q56967041)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30043749%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

title

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30043749%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

1 reference

phase II clinical trial

1 reference

1 reference

systemic lupus erythematosus

1 reference

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30043749%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

4

Kenneth C Kalunian

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30043749%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

author name string

Daniel J Wallace

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30043749%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Richard A Furie

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30043749%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Yoshiya Tanaka

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30043749%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Marta Mosca

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30043749%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Thomas Dörner

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30043749%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Mario H Cardiel

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30043749%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Elisa Gomez

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30043749%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Tara Carmack

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30043749%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Amy M DeLozier

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30043749%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Jonathan M Janes

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30043749%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Matthew D Linnik

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30043749%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Stephanie de Bono

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30043749%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Maria E Silk

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30043749%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Robert W Hoffman

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30043749%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Michelle A Petri

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30043749%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

language of work or name

English

0 references

publication date

1 July 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30043749%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30043749%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

volume

392

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30043749%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

issue

10143

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30043749%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

page(s)

222-231

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30043749%20AND%20SRC:MED&resulttype=core&format=json

New insights into the immunopathogenesis of systemic lupus erythematosus.

14 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931363-1

7 January 2021

Immunopathogenic mechanisms of systemic autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931363-1

7 January 2021

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931363-1

7 January 2021

Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931363-1

7 January 2021

Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931363-1

7 January 2021

The 1982 revised criteria for the classification of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931363-1

7 January 2021

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931363-1

7 January 2021

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931363-1

7 January 2021

Baricitinib in Patients with Refractory Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931363-1

7 January 2021

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931363-1

7 January 2021

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931363-1

7 January 2021

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931363-1

7 January 2021

Efficacy and safety of fezakinumab (an anti-IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments - A randomized, double-blind, phase 2a trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931363-1

7 January 2021

A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931363-1

7 January 2021

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931363-1

7 January 2021

Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931363-1

7 January 2021

Changes in quality of life in the first 5 years of disease in a multicenter cohort of patients with systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931363-1

7 January 2021

Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931363-1

7 January 2021

Disease-specific patient reported outcome tools for systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931363-1

7 January 2021

Relationship between health-related quality of life, disease activity and disease damage in a prospective international multicenter cohort of childhood onset systemic lupus erythematosus patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931363-1

7 January 2021

Novel evidence-based systemic lupus erythematosus responder index

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931363-1

7 January 2021

Emerging Therapeutics for the Control of Chronic Graft-versus-Host Disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931363-1

7 January 2021

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931363-1

7 January 2021

Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931363-1

7 January 2021

Lupus community panel proposals for optimising clinical trials: 2018.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931363-1

7 January 2021

Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931363-1

7 January 2021

10.1016/S0140-6736(18)31363-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30043749%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

1 reference